Trial Profile
A multinational, randomized, double-blind study, comparing the efficacy of aflibercept once every 2 weeks versus placebo in patients with metastatic colorectal cancer (MCRC) treated with irinotecan/5-FU combination (FOLFIRI) after failure of an oxaliplatin based regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms VELOUR
- Sponsors Sanofi
- 14 Nov 2019 Results of post hoc analysis investigating the effect of plasma growth factor levels on patient outcomes in patients with mCRC treated with aflibercept versus placebo in the VELOUR trial published in the Clinical Cancer Research
- 21 Jan 2017 Results (n=553) presented at the 2017 Gastrointestinal Cancers Symposium
- 26 Dec 2015 Post hoc analysis results published in the Targeted Oncology.